SpineGuard SA (ALSGD) Fair Value & Analysis
Healthcare · FR · Market cap €7.9M
Fair value as of: Jul 13, 2026
From 1 valuation models · updated 28 days ago
Share price +2.5% over the past month.
Below-average quality, and screening another 80% overvalued on our models.
What matters now
- Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 13, 2026.
How to read this chart
60‑month range €0.0768 – €1.50 · the €0.0856 price screens above the €0.0170 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 13, 2026.
Analysis
SpineGuard SA (ALSGD) currently trades at €0.0856, while our model-based Fair Value estimate is €0.0170, implying the stock looks roughly 80.1% overvalued today. The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, SpineGuard SA generated revenue of €3.8M at a net margin of -55.0%. Revenue declined 25.7% year over year. It earns a return on equity of -44.1%. Fundamentals as of Jul 13, 2026
The share trades about 60% below its 52-week high and 18% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -80%, ALSGD screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when ALSGD reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 35 · Market factors (momentum, volatility) 26
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
SpineGuard SA provides designs, develops, and markets medical devices for spine in France and internationally. The company offers PediGuard drilling instruments comprising straight, curved, cannulated, psifguard, and threaded PediGuard products; and DSG smart screw that allows for one step screw placement treatment.
Full company description
SpineGuard SA provides designs, develops, and markets medical devices for spine in France and internationally. The company offers PediGuard drilling instruments comprising straight, curved, cannulated, psifguard, and threaded PediGuard products; and DSG smart screw that allows for one step screw placement treatment. It also provides DSG (Dynamic Surgical Guidance) Connect app that allows collection and visualization of the signal measured at the tip of DSG Connect devices during pedicle drilling, as well as DSG for orthopedic robots and dental implantology products. SpineGuard SA was incorporated in 2009 and is headquartered in Vincennes, France.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
SpineGuard SA reported revenue of €3.8M in FY2025 versus €4.4M in FY2021, a compound −3.9%/yr. Reported net income was −€2.1M in FY2025.
ALSGD screens 80% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare SpineGuard SA with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is SpineGuard SA (ALSGD) overvalued or undervalued?
What is the fair value of ALSGD?
What is the quality score of ALSGD?
What is the revenue of SpineGuard SA (ALSGD)?
What is the net profit margin of ALSGD?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track SpineGuard SA and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.